Last Week’s Hot Topic On Pulmonary Fibrosis
Last week’s hot topic on pulmonary fibrosis was NY Times Covers Story of IPF Patient’s Progress with Esbriet Treatment written by Isaura Santos.
This article follows a story covered by the NY Times, about an IPF patient’s progress with Esbriet treatment. “I’ve experienced no change in my condition, no major deterioration since I started on Esbriet,” says Daniel Castner in an exclusive interview with The New York Times. “When I was first diagnosed, I started thinking about the last things I’d get to see before I died,” he said in the interview. “Now I don’t think about death.”
Esbriet (pirfenidone), marketed by Roche through its subsidiary Genentech, is an anti-fibrotic drug thought to act by decreasing the production of collagen and growth and inflammatory factors, ultimately leading to a reduction in lung fibrosis.